We show that MP can be used to allocate resources to treatments within and between patient populations, using a policy-relevant example. The outcome is.

Slides:



Advertisements
Similar presentations
How do we achieve cost effective cancer treatments in the UK? Professor Peter Littlejohns Department of Public Health and Primary Care.
Advertisements

 Introduction  Simple Framework: The Margin Rule  Model with Product Differentiation, Variable Proportions and Bypass  Model with multiple inputs.
1 Economic Cost of Wait Times in Canada: Preliminary Assumptions and Findings ©2006 The Centre for Spatial Economics Robin Somerville Director, Corporate.
Making Decisions in Health Care: Cost-effectiveness and the Value of Evidence Karl Claxton Centre for Health Economics, Department of Economics and Related.
1 Value of Information Yot Teerawattananon, MD International Health Policy Program, Ministry of Public Health PhD candidate in Health Economics, University.
Transforming the cost-effectiveness threshold into a ‘value threshold’ Initial findings from a simulation model Mike Paulden and Christopher McCabe.
Optimal Drug Development Programs and Efficient Licensing and Reimbursement Regimens Neil Hawkins Karl Claxton CENTRE FOR HEALTH ECONOMICS.
Balancing efficiency and equity in formal economic evaluation of health care. Erik Nord, Senior Researcher, Norwegian Institute of Public Health, Professor.
The Allocation of Shared Fixed Costs Fairness versus Efficiency H. Paul Williams -London School of Economics Martin Butler - University College Dublin.
317_L33, April 4, 2008, J. Schaafsma 1 Review of the Last Lecture Finished our discussion of models of not-for-profit acute care hospitals began our discussion.
Government and Health Care Roughly 15 cents of every dollar spent in US is on health care US health care spending equaled $5841 per person in 2002 Governments.
End-of-life premiums in reimbursement decision making Christopher McCabe PhD Capital Health Endowed Research Chair University of Alberta.
Government and Health Care Roughly 15 cents of every dollar spent in US is on health care US health care spending equaled $5841 per person in 2002 Governments.
1. 2 Can Cost-effectiveness Analysis Address Vertical Equity Concerns? Mira Johri Jeffrey S Hoch Greg S Zaric Ahmed Bayoumi.
The Cost-Effectiveness and Value of Information Associated with Biologic Drugs for the Treatment of Psoriatic Arthritis Y Bravo Vergel, N Hawkins, C Asseburg,
Michael Rawlins Chairman, National Institute for Health and Clinical Excellence, London Emeritus Professor, University of Newcastle upon Tyne Honorary.
The Use of Economic Evaluation For Decision Making: Methodological Opportunities and Challenges Mark Sculpher Karl Claxton Centre for Health Economics.
Theory of Consumer Behavior
Results 2 (cont’d) c) Long term observational data on the duration of effective response Observational data on n=50 has EVSI = £867 d) Collect data on.
COST–EFFECTIVENESS ANALYSIS AND COST-UTILITY ANALYSIS
Health care decision making Dr. Giampiero Favato presented at the University Program in Health Economics Ragusa, June 2008.
Gareth D. Myles University of Exeter.  The book advances the theory of cost benefit in directions beneficial for EU policy  It builds on the best of.
AGEC 608 Lecture 17, p. 1 AGEC 608: Lecture 17 Objective: Review the main aspects of cost- effectiveness analysis (CEA) and cost-utility analysis (CUA).
Chapter 5: Theory of Consumer Behavior
The National Institute for Clinical Excellence in the UK – Experience and Impact Mark Sculpher Professor of Health Economics Centre for Health Economics.
TOPICS 1. FINANCIAL DECISIONS, INVESTMENT DECISIONS AND DIVIDEND DECISIONS 2. FINANCIAL MANAGEMENT PROCESS 3.PROFIT MAXIMIZATION AND WEALTH MAXIMIZATION.
Simon Walker Centre for Health Economics, University of York Appropriate perspectives for health care decisions.
EVIDENCE BASED MEDICINE Health economics Ross Lawrenson.
CAROL BEAVER Senior Research Fellow Centre for Chronic Disease University of Qld, Australia Consultant Health Economist MVP/WHO/WPRO Relevance of undertaking.
HTA – Cost Containment or Quality Instrument? Bengt Jönsson Stockholm School of Economic.
Cost-Effectiveness Thresholds Professor of Health Economics
The return of the 5 year plan Mathematical programming for allocation of health care resources David Epstein, Karl Claxton, Mark Sculpher (CHE) Zaid Chalabi.
Stevenson and Ozgur First Edition Introduction to Management Science with Spreadsheets McGraw-Hill/Irwin Copyright © 2007 by The McGraw-Hill Companies,
PRODUCTIVITY AND COSTS IN THE SYSTEM OF HEALTH CARE.
Economic evaluation of drugs for rare diseases CENTRE FOR HEALTH ECONOMICS K Claxton, C McCabe, A Tsuchiya Centre for Health Economics and Department of.
Cost Consequence Analysis Workshop Costing Paul Leak.
Objectives:  Use the utility-maximizing model to explain how consumers choose goods and services.  Use the concept of utility to explain how the law.
1 The Economics of Health Care and New Technologies Friday October 18, 2002 Between Technology and Humanity, Brussels Jan Busschbach PhD, –Department of.
Chapter 5 Dynamic Efficiency and Sustainable Development
4-1 Economics: Theory Through Applications. 4-2 This work is licensed under the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported License.
PANEL SESSION: MODELLING HETEROGENEITY IN COST-EFFECTIVENESS ANALYSIS Modelling variation for decision making Mark Sculpher, PhD Centre for Health Economics,
Matching Analyses to Decisions: Can we Ever Make Economic Evaluations Generalisable Across Jurisdictions? Mark Sculpher Mike Drummond Centre for Health.
Utility- is the satisfaction you receive from consuming a good or service Total utility is the number of units of utility that a consumer gains from consuming.
Chapter Five The Demand Curve and the Behavior of Consumers.
Perfect Competition CHAPTER 11. What Is Perfect Competition? Perfect competition is an industry in which  Many firms sell identical products to many.
Health Policy Analysis: Chapters 10, 11 and 14 Nutchanart Bunthumporn Beth Faiman.
The Value of Reference Case Methods for Resource Allocation Decision Making Mark Sculpher, PhD Professor of Health Economics Centre for Health Economics.
© University of South Wales Royal College of Speech and Language Therapists Outcomes Conference and Hub Launch Belfast, May 1, 2014 Running a tight ship:
If we followed NICE guidelines and treated people with diabetes earlier, patients and the NHS would benefit from a reduction in complications, mortality.
The determinants of change in the cost-effectiveness threshold Mike Paulden, MSc 1 James O’Mahony, PhD 2 Christopher McCabe, PhD 1 1 Department of Emergency.
Making Economic Evaluation Fit for Purpose to Support Decisions Mark Sculpher, PhD Centre for Health Economics University of York, UK The Third Annual.
P4 Advanced Investment Appraisal. 2 2 Section C: Advanced Investment Appraisal C1. Discounted cash flow techniques and the use of free cash flows. C2.
Economics for Commissioning Angela Bate. IHS, Newcastle University UK.
17 Costs and break-even © Malcolm Surridge and Andrew Gillespie 2016.
Cost effectiveness Analysis: Valuing Health; Valuing Research!
HEALTH ECONOMICS BASICS
Linear Programming: Sensitivity Analysis and Duality
Rita Faria Research fellow at the Centre for Health Economics
Cost of Economic Non-Cooperation to Consumers in South Asia
Resource Allocation in Health Care
Chapter 5 Theory of Consumer Behavior
Theory of Consumer Behavior
Chapter 5.
Health care decision making
Why do/should we do economic evaluation?
Luz María Peña-Longobardo & Juan Oliva-Moreno
Chapter 5: Theory of Consumer Behavior
Chapter 5: Theory of Consumer Behavior
Rita Faria, MSc Centre for Health Economics University of York, UK
Presentation transcript:

We show that MP can be used to allocate resources to treatments within and between patient populations, using a policy-relevant example. The outcome is equivalent to the rules of Johanneson and Weinstein (1993), using a cost-effectiveness threshold, if one is willing to accept the resulting level of expenditure as the budget. MP is able to generalise these rules, to accommodate constraints such alternative budgetary rules about the timing of expenditure, or incorporate indivisibilities (and other equity concerns). We show the efficiency loss from these additional constraints and show that the effect of equity concerns will vary from patient population to population. Mathematical programming for the optimal allocation of healthcare resources D Epstein 1, Z Chalabi 2, K Claxton 1, M Sculpher 1 1 Centre for Health Economics, York U.K. 2 London School of Hygiene & Tropical Medicine U.K. RESULTS METHODS AIMS BACKGROUND POLICY EXAMPLE Table1: QALY loss with alternative budget rules The standard decision rules of cost-effectiveness analysis either require the decision maker to set a threshold willingness to pay for additional health care or to set an overall fixed budget. In practice, neither are generally taken, but instead an arbitrary decision rule is followed which: may not be consistent with the overall budget may lead to an allocation of resources which is less than optimal is unable to identify the programme which should be displaced at the margin We aim to show, using a policy-relevant example, how mathematical programming (MP) can be used as a generalisation of the standard decision rules. This allows us: to examine alternative budgetary rules about when expenditure can be incurred, to show that indivisibility in a patient population and other equity concerns can be represented as constraints in the programme The objective : to determine the optimal values of the available healthcare treatments (x ijk ) so as to maximise the gross benefit B subject to an overall budgetary constraint δ, and constraints that ensure all members of each independent healthcare programme k and population group i=1..I k receive one and only one treatment j=1..J k We demonstrate the method using data taken from the 6 th and 7 th wave of NICE appraisals. We assume all treatments must be provided from within a fixed budget. We show results for a range of possible budgets. Total Health Benefits (QALYs) over T years, relative to current care Figure 1: The shadow price (QALYs per additional £million) of the overall budget constraint at different values of the overall budget, and corresponding threshold cost per QALY Threshold = £40,300 per QALY Budget rule Health gain (QALY) Opportunity Loss (QALY) Budget spent £m No constraint 73170£180 Maximum health gain is obtained if there are no constraints about when the budget can be spent (for a budget of £180m) Equal phasing £103 If the total budget (δ) is divided into equal sized maximum annual budgets over T=15 years, there is an opportunity loss compared with no restrictions, and not all the budget can be spent All in 1st 5 years £75 If the budget must be spent in the first five years, and none thereafter, treatments that have costs beyond 5 years are only permitted if their costs are offset by others that are cost saving in those periods Health gain (QALY) Opportunity Loss No equity constraint35860 Health gain for a budget of £180m and an ‘equal phasing’ budget constraint Indivisibility in popn We impose an equity rule that all members of a particular population group and healthcare programme are treated the same way Indivisibility in popn The effect of the equity concern is different in population 2 Indivisibility in all patient populations We impose the equity rule that all patients in each population group and healthcare programme are treated the same way. In this case, the additional constraints (other than indivisibility in population 1) are not binding Table 2: QALY loss with indivisibilities (horizontal equity) CONCLUSIONS Threshold = £10,500 per QALY Decision variables are the proportion of population i and healthcare programme k to receive treatment j All members of each programme and population group receive one and only one treatment The shadow price falls (or the threshold cost per QALY rises) as the budget increases C(t) are the costs at time t (relative to current care), that is: